DelveInsight’s “Acute on Chronic Liver Failure – Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Acute on Chronic Liver Failure market share of the individual therapies, current and forecasted Acute on Chronic Liver Failure market size from 2019 to 2032 segmented by seven major markets. The report also offers current Acute on Chronic Liver Failure therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute on Chronic Liver Failure market.
Key Takeaways from the Acute on Chronic Liver Failure Market Report
- According to DelveInsight estimates, the Acute on Chronic Liver Failure market size is expected to grow significantly at a considerable CAGR by 2032.
- Both hepatic (alcohol-induced liver injury) and extrahepatic (bacterial infections or gastrointestinal hemorrhage) disorders were the most common precipitating disorders for acutely decompensated cirrhosis, with or without ACLF.
- Globally, key Acute on Chronic Liver Failure companies such as Promethera Biosciences, Akaza Bioscience, RHEACELL, Tianjin Weikai Bioeng., Ltd., Steminent Biotherapeutics Inc., Martin Pharmaceuticals, Inc., GNI Group Ltd., Versantis, GENFIT, and others are developing novel Acute on Chronic Liver Failure drugs that can be available in the Acute on Chronic Liver Failure market in the upcoming years.
- Promising Acute on Chronic Liver Failure therapies in the pipeline include Albutein (PE-A 5%), HepaStem, VS-01, and others.
- In November 2022, GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients suffering from liver diseases with significant unmet medical needs, announced the highlights of its Pipeline Day events, which reviewed the Company’s clinical progress and recent strategic updates.
- In September 2022, In a small-time buyout, Genfit SA agreed to acquire Versantis, a Swiss startup, for CHF40 million upfront.
- In June 2022, Versantis, a clinical-stage biotechnology company developing novel therapies for orphan and pediatric liver diseases, announced today data demonstrating that both single and repeated intraperitoneal administrations of VS-01 reduced the concentrations of several metabolites in the blood associated with infection-related acute-on-chronic liver failure (ACLF) and multiple organ failure (OF) associated with ACLF.
Discover more about therapies set to grab major Acute on Chronic Liver Failure market share @ Acute on Chronic Liver Failure Market Report
Acute on Chronic Liver Failure Overview
The term ‘acute-on-chronic liver failure (ACLF)’ refers to a sudden and potentially fatal worsening of clinical conditions in patients with cirrhosis or chronic liver disease. ACLF is a severe condition with a high morbidity and mortality rate. The European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) Consortium defines ACLF as the failure of one of the six major organ systems. The CLIF-C Organ Failure scale is used to assess the failure of each organ system.
According to NACSELD, the most common organ system failures were brain (36%), circulatory (16%), kidney (13%), and respiratory (9%). 3 The observed 30-day mortality rate gradually increased from 4% in patients with no OF to 27%, 49%, 64%, and 77% in patients with 1, 2, 3, or 4 OFs, respectively.
Learn more about the Acute on Chronic Liver Failure treatment guidelines @ ACLF Guidelines
Acute on Chronic Liver Failure Epidemiological Insights
According to Delveinsight, grade 1 cases accounted for the maximum number of ACLF cases.
DelveInsight’s analysis shows that the cases of ACLF show an increasing trend in the forecasted period (2019–2032) in the United States.
The ACLF market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Prevalence of ACLF
- Prevalent cases of ACLF by Grades
- Organ failures associated with ACLF
- Potential precipitating events of ACLF
Download the report to understand which factors are driving Acute on Chronic Liver Failure epidemiology trends @ Acute on Chronic Liver Failure Epidemiological Insights
Acute on Chronic Liver Failure Treatment Market
There is currently no specific treatment available for ACLF patients. ACLF management includes etiology-based treatment, controlling and treating complications, providing an artificial liver support system, and performing a liver transplant. Patients with ACLF should preferably be admitted to transplant centers. Organ functions must be closely monitored, and organ-specific treatment is required to prevent multiorgan failure.
The main principles of management in these patients are to support each failing organ and promote hepatic gland recovery. The current treatment consists of detoxification devices, antiviral therapy, and liver transplantation.
To know more about Acute on Chronic Liver Failure treatment options, visit @ ACLF Drugs
Acute on Chronic Liver Failure Pipeline Therapies
- Albutein (PE-A 5%)
- HepaStem
- VS-01
Acute on Chronic Liver Failure Key Companies
- Promethera Biosciences
- Akaza Bioscience
- RHEACELL
- Tianjin Weikai Bioeng., Ltd.
- Steminent Biotherapeutics Inc.
- Martin Pharmaceuticals, Inc.
- GNI Group Ltd.
- Versantis
- GENFIT
Learn more about the Acute on Chronic Liver Failure therapies in clinical trials @ New Treatment for ACLF
Acute on Chronic Liver Failure Market Dynamics
Many medical factors influence the global acute liver failure treatment market. Drug-induced acute liver failure is one of the common factors driving the acute liver treatment market. For example, excessive acetaminophen dosage has been identified as the leading cause of acute liver failure in the United States.
As per DelveInsight analysis, Among the EU-5 countries, Germany accounts for the highest market size of the Acute-on-Chronic Liver Failure (ACLF) Market.
In the last five years, the field of ACLF has moved very quickly to meet the current unmet need. The availability of a large volume of published data from the East and West has allowed the initial definitions to be reassessed. Attempts to prevent, mitigate, or reverse the ongoing injury would allow for the restoration of hepatic synthetic functions and the reversal of liver damage. Early predictors of mortality and irreversibility of the condition would pave the way for such patients to receive priority liver transplantation.
Scope of the Acute on Chronic Liver Failure Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Acute on Chronic Liver Failure Companies: Promethera Biosciences, Akaza Bioscience, RHEACELL, Tianjin Weikai Bioeng., Ltd., Steminent Biotherapeutics Inc., Martin Pharmaceuticals, Inc., GNI Group Ltd., Versantis, GENFIT (EPA: GNFT), and others
- Key Acute on Chronic Liver Failure Therapies: Albutein (PE-A 5%), HepaStem, VS-01, and others
- Therapeutic Assessment: Acute on Chronic Liver Failure current marketed and emerging therapies
- Acute on Chronic Liver Failure Market Dynamics: Acute on Chronic Liver Failure market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Acute on Chronic Liver Failure Market Access and Reimbursement
Discover more about Acute on Chronic Liver Failure drugs in development @ ACLF Clinical Trials
Table of Contents
| 1. | Acute on Chronic Liver Failure Market Key Insights |
| 2. | Acute on Chronic Liver Failure Market Report Introduction |
| 3. | Acute on Chronic Liver Failure Market Overview at a Glance |
| 4. | Acute on Chronic Liver Failure Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Acute on Chronic Liver Failure Treatment and Management |
| 7. | Acute on Chronic Liver Failure Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Acute on Chronic Liver Failure Marketed Drugs |
| 10. | Acute on Chronic Liver Failure Emerging Drugs |
| 11. | Seven Major Acute on Chronic Liver Failure Market Analysis |
| 12. | Acute on Chronic Liver Failure Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Acute on Chronic Liver Failure Market Drivers |
| 16. | Acute on Chronic Liver Failure Market Barriers |
| 17. | Unmet Needs |
| 18. | SWOT Analysis |
| 19. | Appendix |
| 20. | DelveInsight Capabilities |
| 21. | Disclaimer |
| 22. | About DelveInsight |
Get in touch with our Business executive @ Healthcare Due Diligence Services
Related Reports
Acute On Chronic Liver Failure Pipeline
Acute On Chronic Liver Failure Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ACLF companies, including Steminent Biotherapeutics Inc., Martin Pharmaceuticals, Inc., GNI Group Ltd., Versantis, GENFIT, among others.
Liver Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key liver cancer companies, including Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, among others.
Advanced Liver Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced liver cancer companies including Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, among others.
Non-Alcoholic Fatty Liver Disease Market
Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-alcoholic fatty liver disease companies including AstraZeneca, Novartis, Pfizer, Roche, among others.
Nonalcoholic Steatohepatitis Market
Nonalcoholic Steatohepatitis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key nonalcoholic steatohepatitis companies including Zydus Cadila, Novartis, AstraZeneca, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Thyroid Cancer Market | Hemostasis Market | Peptic Ulcers Market
Related Healthcare Services
- Healthcare Business Consulting
- Healthcare Competitive Intelligence Services
- Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187